NBT Bancorp Insider Notice — 19,603 Shares Proposed for Sale via UBS
Rhea-AI Filing Summary
Form 144 submitted for NBT Bancorp Inc (ticker NBTB) notifies a proposed sale of 19,603 shares of common stock through UBS Financial Services Inc on the NASDAQ, with an aggregate market value of $850,997.52 and 52,394,805 shares outstanding. The shares offered represent approximately 0.037% of outstanding common stock. The notice lists the securities as having been acquired in multiple open-market purchases between 2006 and 2011 and indicates no sales in the past three months by the same person.
The disclosure is a routine insider sale notice: it specifies the broker, the number of shares to be sold, the acquisition history, and the approximate sale date of 08/13/2025, but contains no additional financial performance or forward-looking information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Proposed sale of 19,603 NBTB shares (~0.037% of outstanding) is small in size and appears immaterial to capitalization.
The Form 144 details a proposed sale with an aggregate market value of $850,997.52 executed through UBS Financial Services Inc. Against 52,394,805 shares outstanding, the position equals roughly 0.037% of the float, indicating limited direct impact on supply or valuation. The filing also shows no securities sold during the past three months by the reporting person, and the underlying shares were acquired via multiple open-market purchases between 2006 and 2011. Impact is therefore assessed as neutral from a market-metrics perspective.
TL;DR: The notice is a standard insider disclosure documenting past open-market purchases and a planned sale; procedural compliance appears satisfied.
The Form 144 provides the required details: broker name and address, class of security, number of shares to be sold, aggregate market value, acquisition dates and methods, and an approximate sale date of 08/13/2025. The acquisition history lists multiple open-market purchases from 2006–2011, and the filer certifies no undisclosed material adverse information. Given the small size of the proposed sale relative to outstanding shares, this appears to be a routine compliance disclosure rather than a governance concern.